DE1617521C3 - Verfahren zur Herstellung von Sulfonamid-Potentiator-Lösungen - Google Patents
Verfahren zur Herstellung von Sulfonamid-Potentiator-LösungenInfo
- Publication number
- DE1617521C3 DE1617521C3 DE1617521A DEH0062521A DE1617521C3 DE 1617521 C3 DE1617521 C3 DE 1617521C3 DE 1617521 A DE1617521 A DE 1617521A DE H0062521 A DEH0062521 A DE H0062521A DE 1617521 C3 DE1617521 C3 DE 1617521C3
- Authority
- DE
- Germany
- Prior art keywords
- solutions
- sulfonamide
- preparation
- potentiator
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940124530 sulfonamide Drugs 0.000 title claims description 14
- 150000003456 sulfonamides Chemical class 0.000 title claims description 13
- 238000002360 preparation method Methods 0.000 title claims description 7
- 238000000034 method Methods 0.000 title claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 229940074076 glycerol formal Drugs 0.000 claims description 6
- LDBTVAXGKYIFHO-UHFFFAOYSA-N diaveridine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=CN=C(N)N=C1N LDBTVAXGKYIFHO-UHFFFAOYSA-N 0.000 claims description 4
- MAIVCOSUIAQGHY-UHFFFAOYSA-N 4-amino-2,3-dimethoxy-n-pyrimidin-2-ylbenzenesulfonamide Chemical compound COC1=C(N)C=CC(S(=O)(=O)NC=2N=CC=CN=2)=C1OC MAIVCOSUIAQGHY-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- NHUHCSRWZMLRLA-UHFFFAOYSA-N Sulfisoxazole Chemical compound CC1=NOC(NS(=O)(=O)C=2C=CC(N)=CC=2)=C1C NHUHCSRWZMLRLA-UHFFFAOYSA-N 0.000 claims description 2
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 claims description 2
- 229940102223 injectable solution Drugs 0.000 claims 1
- -1 sulfonamide salt Chemical class 0.000 claims 1
- 238000010792 warming Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000003978 infusion fluid Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- VCKSNYNNVSOWEE-UHFFFAOYSA-N 1,3-dioxan-5-ol Chemical compound OC1COCOC1 VCKSNYNNVSOWEE-UHFFFAOYSA-N 0.000 description 1
- BOHGAOWOIJMTPZ-UHFFFAOYSA-N 1,3-dioxolan-4-ylmethanol Chemical compound OCC1COCO1 BOHGAOWOIJMTPZ-UHFFFAOYSA-N 0.000 description 1
- NHZLNPMOSADWGC-UHFFFAOYSA-N 4-amino-N-(2-quinoxalinyl)benzenesulfonamide Chemical compound C1=CC(N)=CC=C1S(=O)(=O)NC1=CN=C(C=CC=C2)C2=N1 NHZLNPMOSADWGC-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 229940003898 combination of sulfonamides Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electric Connection Of Electric Components To Printed Circuits (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH671666 | 1966-05-09 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DE1617521A1 DE1617521A1 (de) | 1972-02-10 |
| DE1617521B2 DE1617521B2 (de) | 1979-01-04 |
| DE1617521C3 true DE1617521C3 (de) | 1979-09-06 |
Family
ID=74187416
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE1617521A Expired DE1617521C3 (de) | 1966-05-09 | 1967-04-24 | Verfahren zur Herstellung von Sulfonamid-Potentiator-Lösungen |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US3551564A (enExample) |
| JP (1) | JPS5017524B1 (enExample) |
| BE (1) | BE698102A (enExample) |
| CH (1) | CH544053A (enExample) |
| DE (1) | DE1617521C3 (enExample) |
| DK (1) | DK117520B (enExample) |
| ES (1) | ES340262A1 (enExample) |
| FI (1) | FI48975C (enExample) |
| FR (1) | FR1523606A (enExample) |
| GB (1) | GB1176395A (enExample) |
| GR (1) | GR35814B (enExample) |
| IL (1) | IL27876A (enExample) |
| IT (1) | IT1143624B (enExample) |
| NL (1) | NL140736B (enExample) |
| NO (1) | NO127486B (enExample) |
| SE (1) | SE348112B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZM3271A1 (en) * | 1970-03-13 | 1972-10-23 | Wellcome Found | Improvements in or relating to injectable therapeutic compositions |
| US3728452A (en) * | 1971-01-20 | 1973-04-17 | Abic Ltd | Water-soluble composition comprising sulfadimidine and pyrimethamine |
| IT1044231B (it) * | 1972-03-16 | 1980-03-20 | Hoffmann La Roche | Combinazione di sostanze attive utile per combattere infezioni da batteri gram positivi e gran negativi |
| DE2342213C3 (de) * | 1972-10-12 | 1979-10-18 | F. Hoffmann-La Roche & Co Ag, Basel (Schweiz) | Verwendung von potenzierten SuIf onamiden bei der Behandlung oder Verhinderung von Fischinfektionen |
| US3985876A (en) * | 1973-01-05 | 1976-10-12 | Burroughs Wellcome Co. | Chemotherapeutic solutions containing a sulphur and a salt of a 2,4-diamino-5-benzylpyrimidine |
| GB1485382A (en) * | 1973-09-24 | 1977-09-08 | Wellcome Found | Injectable therapeutic compositions |
| GB1485383A (en) * | 1973-09-24 | 1977-09-08 | Wellcome Found | Injectable non-aqueous therapeutic compositions |
| US4039543A (en) * | 1974-12-24 | 1977-08-02 | Hoffmann-La Roche Inc. | Benzylpyrimidines |
| DK136934B (da) * | 1976-02-06 | 1977-12-19 | Rosco As | Fremgangsmåde til fremstilling af en klar, stabil, injicerbar opløsning indeholdende et sulfonamid og en potentiator. |
| DE2631780C3 (de) * | 1976-07-15 | 1981-11-19 | Basf Ag, 6700 Ludwigshafen | Sulfonamid-Trimethoprim-Lösungen |
| DE2731013C2 (de) * | 1977-07-08 | 1982-07-15 | Lentia Gmbh | Verfahren zur Herstellung einer wäßrigen Infusionslösung |
| ZW9979A1 (en) * | 1978-05-24 | 1980-12-24 | Wellcome Found | Benzylpyrimidine compositions |
| EP0007591B1 (de) | 1978-08-01 | 1982-07-28 | Ciba-Geigy Ag | Stabile flüssige Arzneimittelformulierung auf Basis von 2,6-Diamino-5-(3',4',5'-trimethoxybenzyl)-pyrimidin(Trimethoprim) und einem Sulfonamid, Verfahren zu ihrer Herstellung und ihre Verwendung |
| US4303643A (en) * | 1979-07-05 | 1981-12-01 | Pfizer Inc. | Sulfonamide compositions |
| HU180740B (en) * | 1979-11-27 | 1983-04-29 | Egyt Gyogyszervegyeszeti Gyar | Process for producing sulfonamide-containing,injectable pharmaceutical composition of prolongated activity |
| AR220263A1 (es) * | 1980-02-19 | 1980-10-15 | Bago Lab Sa | Procedimiento para obtener una preparacion inyectable de sulfonamida potenciada de baja irritabilidad |
| CH647412A5 (de) * | 1980-03-25 | 1985-01-31 | Hoffmann La Roche | Pharmazeutische praeparate. |
| US4374826A (en) * | 1980-07-21 | 1983-02-22 | Pfizer Inc. | Sulfonamide compositions |
| EP4417701A4 (en) * | 2021-10-12 | 2025-03-05 | Daan Gene Co., Ltd. | IN VITRO PRESERVATIVES FOR DIAGNOSTIC REAGENTS AND USE THEREOF |
-
1966
- 1966-05-09 CH CH280973A patent/CH544053A/de not_active IP Right Cessation
-
1967
- 1967-04-24 DE DE1617521A patent/DE1617521C3/de not_active Expired
- 1967-04-28 US US634472A patent/US3551564A/en not_active Expired - Lifetime
- 1967-04-28 IL IL27876A patent/IL27876A/xx unknown
- 1967-05-03 FI FI671280A patent/FI48975C/fi active
- 1967-05-08 JP JP42028760A patent/JPS5017524B1/ja active Pending
- 1967-05-08 SE SE06386/67A patent/SE348112B/xx unknown
- 1967-05-08 ES ES340262A patent/ES340262A1/es not_active Expired
- 1967-05-08 BE BE698102D patent/BE698102A/xx not_active IP Right Cessation
- 1967-05-08 GB GB21230/67A patent/GB1176395A/en not_active Expired
- 1967-05-08 GR GR670135814A patent/GR35814B/el unknown
- 1967-05-08 FR FR105482A patent/FR1523606A/fr not_active Expired
- 1967-05-08 DK DK241967AA patent/DK117520B/da not_active IP Right Cessation
- 1967-05-08 NO NO00168048A patent/NO127486B/no unknown
- 1967-05-09 IT IT15891/67A patent/IT1143624B/it active
- 1967-05-09 NL NL676706474A patent/NL140736B/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NL140736B (nl) | 1974-01-15 |
| IL27876A (en) | 1971-10-20 |
| CH544053A (de) | 1973-11-15 |
| NO127486B (enExample) | 1973-07-02 |
| DK117520B (da) | 1970-05-04 |
| FI48975B (enExample) | 1974-12-02 |
| FR1523606A (fr) | 1968-05-03 |
| US3551564A (en) | 1970-12-29 |
| SE348112B (enExample) | 1972-08-28 |
| FI48975C (fi) | 1975-03-10 |
| GR35814B (el) | 1968-11-04 |
| NL6706474A (enExample) | 1967-11-10 |
| BE698102A (enExample) | 1967-11-08 |
| IT1143624B (it) | 1986-10-22 |
| JPS5017524B1 (enExample) | 1975-06-21 |
| DE1617521A1 (de) | 1972-02-10 |
| GB1176395A (en) | 1970-01-01 |
| ES340262A1 (es) | 1968-06-01 |
| DE1617521B2 (de) | 1979-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1617521C3 (de) | Verfahren zur Herstellung von Sulfonamid-Potentiator-Lösungen | |
| DE69104724T2 (de) | Florfenicol enthaltendes arzneimittel. | |
| EP0177870B1 (de) | Stabilisierte Injektionslösungen von Piroxicam | |
| EP0136470A2 (de) | Injizierbare Lösung zur Behandlung von Entzündungen | |
| DE4139017C2 (de) | Wäßrige Piroxicam-Lösungen und Verfahren zu ihrer Herstellung | |
| DE3623620C2 (enExample) | ||
| EP0187315A2 (de) | Basische Zubereitungen von Chinoloncarbonsäuren | |
| DE602005002495T2 (de) | Injizierbare Formulierung mit Natriumdiclofenac, Beta-Cyclodextrin und einem Polysorbat | |
| DE3416609A1 (de) | 2-amino-3-ethoxycarbonylamino-6-(p-fluor-benzylamino)- pyridin-gluconat und pharmazeutische zubereitungen, die diese substanz enthalten | |
| EP0007591B1 (de) | Stabile flüssige Arzneimittelformulierung auf Basis von 2,6-Diamino-5-(3',4',5'-trimethoxybenzyl)-pyrimidin(Trimethoprim) und einem Sulfonamid, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE1467749A1 (de) | Verfahren zur Herstellung von stabilen Tetracyclinpraeparaten | |
| DE2627706C2 (de) | Verfahren zur Herstellung von neutralen beständigen, mit Wasser zu klaren Lösungen verdünnbaren Sulfonamid-Potentiatorlösungen | |
| DE2731013C2 (de) | Verfahren zur Herstellung einer wäßrigen Infusionslösung | |
| DE68903937T2 (de) | Waessrige elcatonin-loesung enthaltende arzneizubereitung. | |
| DD253569A5 (de) | Verfahren zur herstellung von basischen zubereitungen von chinoloncarbonsaeuren | |
| EP0653210B1 (de) | Intravenös verabreichbare wässrige Lösung von Sulfametrol und Trimethoprim | |
| DE2461570C3 (de) | Arzneimittel für die Behandlung bakterieller Infektionen der Augen und/oder der Ohren und Verfahren zu ihrer Herstellung | |
| DE1792448C3 (de) | Verfahren zur Herstellung von zur parenteralen Verabreichung geeigneten stabilen Lösungen von therapeutisch anwendbaren Benzodiazepinderivaten | |
| DE3237284C2 (enExample) | ||
| AT399817B (de) | Intravenös verabreichbare wässrige sulfametrollösung und verfahren zu ihrer herstellung | |
| DE2538678A1 (de) | Injizierbare loesungen | |
| DE2445401C3 (de) | Injizierbare, einphasige Zubereitung und Verfahren zu ihrer Herstellung | |
| DE2011793C (de) | Parenteral anwendbare 5-Hydroxytetracyclinlösung | |
| DE1692515A1 (de) | Sulfachinoxalin enthaltende Zubereitungen und Verfahren zu deren Herstellung | |
| DE1227613B (de) | Verwendung von Polyaethylenglykolen zum Stabilisieren von Polyaethyleniminen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C3 | Grant after two publication steps (3rd publication) |